Page 512 - Read Online

Yip et al. Hepatoma Res 2020;6:44 I http://dx.doi.org/10.20517/2394-5079.2020.30 Page 7 of 8

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJM, et al. Stereotactic body radiation therapy for primary and
metastatic liver tumors: a single institution phase I-II study. Acta Oncol 2006;45:831-7.
2. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally
advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-9.
3. Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, et al. Outcomes following definitive stereotactic body radiotherapy for patients with
Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014;111:412-7.
4. Andratschke N, Alheid H, Allgäuer M, Becker G, Blanck O, et al. The SBRT database initiative of the German Society for Radiation
Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474
patients with 623 metastases. BMC Cancer 2018;18:283.
5. Scorsetti M, Comito T, Clerici E, Franzese C, Tozzi A, et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome
and prognostic factors of survival after 5 years of follow-up. Radiat Oncol 2018;13:234.
6. Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to
transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017;67:92-9.
7. Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 2005;44:13-22.
8. Reed GB, Cox AJ. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol 1966;48:597-611.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. Clinical management of hepatocellular carcinoma. Conclusions of the
Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-30.
11. Lencioni R, Llovet J. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
12. Vernuccio F, Godfrey D, Meyer M, Williamson H V., Salama JK, et al. Local tumor control and patient outcome using stereotactic
body radiation therapy for hepatocellular carcinoma: iRECIST as a potential substitute for traditional criteria. Am J Roentgenol
2019;213:1232-9.
13. Price TR, Perkins SM, Sandrasegaran K, Henderson MA, Maluccio MA, et al. Evaluation of response after stereotactic body radiotherapy
for hepatocellular carcinoma. Cancer 2012;118:3191-8.
14. Mannina EM, Cardenes HR, Lasley FD, Goodman B, Zook J, et al. Role of Stereotactic body radiation therapy before orthotopic liver
transplantation: retrospective evaluation of pathologic response and outcomes. Int J Radiat Oncol 2017;97:931-8.
15. Takamatsu S, Kozaka K, Kobayashi S, Yoneda N, Yoshida K, et al. Pathology and images of radiation-induced hepatitis: a review article.
Jpn J Radiol 2018;36:241-56.
16. Lall C, Bhargava P, Sandrasegaran K, Shanbhogue AK, Ramsinghani N, et al. Three-dimensional conformal radiation therapy in the liver:
MRI findings along a time continuum. J Comput Assist Tomogr 2015:39:356-64.
17. Park MJ, Kim SY, Yoon SM, Kim JH, Park SH, et al. Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous
hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed
tomography. PLoS One 2014;9:e90327.
18. Kimura T, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, et al. The time course of dynamic computed tomographic appearance of radiation
injury to the cirrhotic liver following stereotactic body radiation therapy for hepatocellular carcinoma. PLoS One 2015;10:e0125231.
19. Ronot M, Asselah T, Paradis V, Michoux N, Dorvillius M, et al. Liver fibrosis in chronic hepatitis C virus infection: Differentiating
minimal from intermediate fibrosis with perfusion CT. Radiology 2010;256:135-42.
20. Yu JI, Park HC, Lim DH, Choi Y, Jung SH, et al. The role of diffusion-weighted magnetic resonance imaging in the treatment response
evaluation of hepatocellular carcinoma patients treated with radiation therapy. Int J Radiat Oncol 2014;89:814-21.
21. Lo CH, Huang WY, Hsiang CW, Lee MS, Lin CS, et al. Prognostic significance of apparent diffusion coefficient in hepatocellular
carcinoma patients treated with stereotactic ablative radiotherapy. Sci Rep 2019;9:14157.
22. Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18 F-fluorodeoxyglucose positron emission tomography for guiding management of
hepatocellular carcinoma. World J Gastroenterol 2019;25:1289-306.
23. Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, et al. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as
predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. J Nucl Med 2013;54:1710-6.
24. Lu RC, She B, Gao WT, Ji YH, Xu DD, et al. Positron-emission tomography for hepatocellular carcinoma: Current status and future
prospects. World J Gastroenterol 2019;25:4682-95.
25. Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, et al. Detection of hepatocellular carcinoma with PET/CT: A prospective
comparison of 18F-Fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010;51:1699-706.
26. Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, et al. Baseline and post-treatment 18F-Fluorocholine PET/CT predicts
outcomes in hepatocellular carcinoma following locoregional therapy. Dig Dis Sci 2020;65:647-57.